Skip to main content

Show 24 results Show all

Important policies for advancing access to subcutaneous DMPA

Offers an overview of key policies that affect introduction and scale-up of injectable contraceptives, including DMPA-SC.

Institutional author(s): PATH
Publication date: 2019

Advocacy Strategy Development Template: Planning to Achieve DMPA-SC Policy Change

A 10-part framework that supports individuals and organizations to develop a high-impact, outcome-oriented policy advocacy strategy.

Institutional author(s): PATH
Publication date: August, 2019

Increasing access to subcutaneous DMPA in Uganda: An advocacy case study

Describes key evidence-building efforts, advocacy actions, and policy changes in Uganda brought about by key partners to increase access to injectable contraception, including DMPA-SC. You can draw on lessons learned from Uganda to inform your policy goals and advocacy strategy for increasing method choice and access with DMPA-SC in your country.

Institutional author(s): PATH
Publication date: August, 2019

DMPA and HIV: What advocates need to know

Summarizes important takeaways for advocates from the latest guidance released by the World Health Organization on hormonal contraception, including DMPA injectables, and HIV for women at high risk of HIV.

Institutional author(s): PATH
Publication date: August, 2019

Expanding Access to Injectable Contraceptives through Pharmacies Toolkit

This toolkit contains resources designed to help pharmacy associations become effective advocates and begin working to change policies in their countries. The toolkit can be adapted to advocate for any injectable contraceptive. The toolkit includes a Resource for Considering DMPA-SC.

Institutional author(s): SHOPS Plus, USAID
Publication date: May, 2019

Tool Web page

Key actions for advocates to advance subcutaneous DMPA

Provides examples of actions that may be useful in advancing access to DMPA-SC, including those that apply to different country stages.

Institutional author(s): PATH
Publication date: August, 2017

Common terms for DMPA injectable contraception

This DMPA-SC advocacy pack brief helps you understand the terms surrounding DMPA injectables to inform your messaging and communication.

Institutional author(s): PATH
Publication date: 2017

DMPA-SC policy and regulatory advocacy landscape

This policy landscape can be leveraged by applicants interested in applying to the DMPA-SC Regulatory Advocacy Catalytic Opportunity Fund (COF). The landscape was originally developed in 2020 to understand policies and regulations, including over-the-counter regulations, that impact women’s access to DMPA-SC and identify short- and long-term advocacy opportunities. In 2022, it was refreshed to understand policy shifts and additional advocacy opportunities in a subset of 12 of the original 18 countries currently eligible for the Regulatory Advocacy COF. Insights from the policy landscape have informed the design and eligibility criteria of the Regulatory Advocacy COF, proactively identified opportunities, and provided frameworks and guidance for interested applicants.

Institutional author(s): Clinton Health Access Initiative (CHAI)
Publication date: 2022


DMPA-SC overbranding and overpackaging in private and social marketing sectors

The desire for private sector family planning programs to have the ability to overbrand/overpackage the Pfizer Inc. DMPA-SC product, Sayana® Press, has existed since initial product introduction planning discussions among global partners in 2008–2009. The PATH-JSI DMPA-SC Access Collaborative solicited input from the team’s regional technical advisors, country coordinators, and local partners to better understand the status of overbranding, and any related advocacy­­, in the countries where we work.

Institutional author(s): PATH, JSI
Publication date: July, 2022

Costs and cost-effectiveness of subcutaneous DMPA through different delivery channels: What new evidence tells us

This brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.

Institutional author(s): PATH
Publication date: October, 2019